melatonin has been researched along with galantamine in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| de Los Ríos, C; Egea, J; Gálvez, E; García, AG; Iriepa, I; León, R; López, MG; Marco-Contelles, J; Moraleda, I; Romero, A; Samadi, A; Villarroya, M | 1 |
| Arce, MP; Conde, S; del Barrio, L; Egea, J; García, AG; González-Muñoz, GC; León, R; López, B; López, MG; Martín-de-Saavedra, MD; Pérez, C; Rodríguez-Franco, MI; Romero, A; Villarroya, M | 1 |
| Ding, K; Huang, L; Jiang, H; Li, X; Luo, Z; Su, T; Wang, X | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Egea, J; García, AG; López, MG; Romero, A | 1 |
| Axwik, KE; Jones, AM; Murch, SJ; Saxena, PK; Smith, A; Turi, CE | 1 |
| Buendia, I; Egea, J; León, R; López, MG; Navarro, E; Negredo, P; Parada, E | 1 |
| Alagiakrishnan, K | 1 |
| Majidazar, R; Naseri, A; Rezazadeh-Gavgani, E; Sadigh-Eteghad, S | 1 |
2 review(s) available for melatonin and galantamine
| Article | Year |
|---|---|
Melatonin based therapies for delirium and dementia.
Topics: Aged; Animals; Antipsychotic Agents; Benzodiazepines; Chronobiology Phenomena; Clinical Trials as Topic; Delirium; Dementia; Drug Therapy, Combination; Galantamine; Humans; Indenes; Melatonin; Memantine; Neuroprotection; Practice Guidelines as Topic | 2016 |
Pharmacotherapy of Alzheimer's disease: an overview of systematic reviews.
Topics: Alzheimer Disease; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Cholinesterase Inhibitors; Donepezil; Galantamine; Glycogen Synthase Kinase 3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Indans; Lithium; Melatonin; Memantine; Neurodegenerative Diseases; Rivastigmine; Systematic Reviews as Topic | 2022 |
7 other study(ies) available for melatonin and galantamine
| Article | Year |
|---|---|
Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Calcium; Catalytic Domain; Cell Death; Cell Line, Tumor; Cholinesterase Inhibitors; Cytotoxins; Electron Transport Chain Complex Proteins; Electrophorus; Glucose; Hippocampus; Humans; Isomerism; Models, Molecular; Naphthyridines; Neuroprotective Agents; Okadaic Acid; Oligomycins; Oxygen; Peptide Fragments; Protein Binding; Protein Phosphatase 2; Rats; Rotenone; Structure-Activity Relationship | 2010 |
N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antineoplastic Agents; Butyrylcholinesterase; Calcium; Cell Death; Cell Survival; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Structure; Okadaic Acid; Peptide Fragments; Phenothiazines; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured | 2011 |
Benzenediol-berberine hybrids: multifunctional agents for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Berberine; Cholinesterase Inhibitors; Coumaric Acids; Humans; Hydroquinones; Melatonin; Mice; Models, Molecular; Molecular Structure; Peptide Fragments; Structure-Activity Relationship | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Synergistic neuroprotective effect of combined low concentrations of galantamine and melatonin against oxidative stress in SH-SY5Y neuroblastoma cells.
Topics: Analysis of Variance; Cell Death; Cell Line, Tumor; Drug Synergism; Galantamine; Histocytochemistry; Humans; Mecamylamine; Melatonin; Neuroblastoma; Neuroprotective Agents; Oxidative Stress; Signal Transduction; Tryptamines | 2010 |
Galanthamine, an anticholinesterase drug, effects plant growth and development in Artemisia tridentate Nutt. via modulation of auxin and neutrotransmitter signaling.
Topics: Acetylcholine; Acetylcholinesterase; Artemisia; Cholinesterase Inhibitors; Culture Techniques; Galantamine; Indoleacetic Acids; Melatonin; Oxidative Stress; Plant Development; Serotonin | 2014 |
Subthreshold Concentrations of Melatonin and Galantamine Improves Pathological AD-Hallmarks in Hippocampal Organotypic Cultures.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents; Antioxidants; Cell Death; Galantamine; Hippocampus; Melatonin; Models, Biological; Neuroprotective Agents; Okadaic Acid; Phosphorylation; Protein Aggregates; Rats, Sprague-Dawley; tau Proteins; Tissue Culture Techniques | 2016 |